Description: Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis. It also manufactures and sells drugs. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in North Melbourne, Australia.
Home Page: www.ampliatx.com
350 Queen Street
Melbourne,
VIC
3000
Australia
Phone:
61 2 8003 3650
Officers
| Name | Title |
|---|---|
| Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D. | CEO, MD & Director |
| Mr. Hamish George | Chief Financial Officer |
| Ms. Rhiannon Jones B.Sc., Ph.D. | Chief Operating Officer |
| Ms. Terrie-Anne Cock Ph.D. | Head of Translational Biology |
| Mr. Andrew John Cooke FAICS, FCIS, FGIA, L.L.B., LLB, MAICD | Company Sec. |
| Dr. Frank Gelder | Founding Scientist |
| Dr. James A. Taylor Ph.D. | Trials Consultant |
| Dr. Michael H. Silverman B.Sc., M.B.A., M.D., F.A.C.P., FACR | Trials Consultant |
| Dr. Benjamin M. Segal | Clinical Consultant |
| Dr. Frederick E. Reno Ph.D. | Toxicology Consultant |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6015 |
| Price-to-Sales TTM: | 3.966 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 0 |